ArticleClinical, cosmetic and investigational dermatology2026
Does Alexithymia Affect Patients with Hidradenitis Suppurativa?
Article in Clinical, cosmetic and investigational dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease associated with substantial psychosocial burden. Alexithymia, characterized by difficulties in identifying and expressing emotions, has been increasingly recognized in chronic disorders. However, data in HS remain limited. This study aimed to assess the prevalence of alexithymia in HS and its relationship with clinical and psychosocial parameters. Material and Methods: This cross-sectional study included 123 consecutive adult HS patients. Disease severity was assessed using Hurley staging and the International Hidradenitis Suppurativa Severity Score System (IHS4). Alexithymia was evaluated with the Toronto Alexithymia Scale (TAS-20). Pain and pruritus were measured using the Numeric Rating Scale. Psychological burden was assessed with Patient Health Questionnaire-9 (PHQ-9), Generalized Anxiety Disorder-7 (GAD-7), and Hospital Anxiety and Depression Scale (HADS), illness acceptance was studied with Acceptance Illness Scale (AIS), while quality of life (QoL) was evaluated using Dermatology Life Quality Index (DLQI) and Hidradenitis Suppurativa Quality of Life (HiSQoL) questionnaire. Results: Alexithymia was identified in 13.8% of patients, while 22.0% presented intermediate levels. The mean TAS-20 score was 46.45 ± 12.75 points. Females showed higher difficulty in identifying feelings (p=0.025). No significant associations were found between total alexithymia scores and disease severity. However, the externally oriented thinking (EOT) domain was significantly higher in more severe disease. TAS-20 scores showed weak correlations with IHS4, pain, and pruritus. Stronger associations were observed with depressive symptoms, anxiety, impaired QoL, and poorer disease acceptance, particularly for the difficulty in identifying feelings domain. Conclusion: Alexithymic traits affect a substantial proportion of HS patients and are primarily associated with psychosocial burden rather than objective disease severity. Assessment of alexithymia, especially its domains, may provide clinically relevant insights and support a more comprehensive, multidisciplinary approach to HS management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.